- Home
- TGTX vs CNR Comparison
TGTX vs CNR Comparison
Compare TGTX & CNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- CNR
- Stock Information
- Founded
- TGTX 1993
- CNR 1864
- Country
- TGTX United States
- CNR United States
- Employees
- TGTX N/A
- CNR N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- CNR Coal Mining
- Sector
- TGTX Health Care
- CNR Energy
- Exchange
- TGTX Nasdaq
- CNR Nasdaq
- Market Cap
- TGTX 4.2B
- CNR 3.8B
- IPO Year
- TGTX 1995
- CNR N/A
- Fundamental
- Price
- TGTX $32.18
- CNR $72.94
- Analyst Decision
- TGTX Strong Buy
- CNR Strong Buy
- Analyst Count
- TGTX 4
- CNR 4
- Target Price
- TGTX $42.50
- CNR $94.75
- AVG Volume (30 Days)
- TGTX 2.0M
- CNR 628.0K
- Earning Date
- TGTX 11-03-2025
- CNR 08-05-2025
- Dividend Yield
- TGTX N/A
- CNR 0.55%
- EPS Growth
- TGTX N/A
- CNR N/A
- EPS
- TGTX 0.36
- CNR 0.51
- Revenue
- TGTX $454,069,000.00
- CNR $3,275,589,000.00
- Revenue This Year
- TGTX $82.58
- CNR $92.77
- Revenue Next Year
- TGTX $44.99
- CNR $9.20
- P/E Ratio
- TGTX $89.78
- CNR $141.65
- Revenue Growth
- TGTX 30.96
- CNR 47.13
- 52 Week Low
- TGTX $21.16
- CNR $58.19
- 52 Week High
- TGTX $46.48
- CNR $134.59
- Technical
- Relative Strength Index (RSI)
- TGTX 57.80
- CNR 49.16
- Support Level
- TGTX $31.34
- CNR $71.83
- Resistance Level
- TGTX $32.57
- CNR $75.67
- Average True Range (ATR)
- TGTX 1.13
- CNR 2.18
- MACD
- TGTX 0.54
- CNR 0.08
- Stochastic Oscillator
- TGTX 76.10
- CNR 44.54
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.